ImmunoPrecise Antibodies has acquired ModiQuest Research BV to create a “single source provider of services across the full antibody discovery value chain,” says CRO.
LabCorp is investing $30m in a new operations center at the former GSK campus in Research Triangle Park with support from a job development grant worth more than $8m.
Pharma must look outward to innovate and find new areas of growth, as research and development productivity and returns on innovation continue to decline, says industry expert.
The mobile health platform from Oracle Health Sciences enables clinical study teams to collect remote patient data from sensors, wearables, and apps – and promises to deliver “a new level of patient centricity.”
Parexel and Meiji Pharmaceutical University have announced a new academic program to develop the biopharmaceutical workforce in Japan and meet the industry’s demand for talent in clinical research.
Pfizer will recruit patients with rare diseases and identify clinical trial sites with support from the TriNetX global health research network, which is becoming "the defacto platform" for research, says CEO.
Frontage Laboratories has acquired Concord Biosciences, taking a “significant step” towards the company’s goal of building a global organization, says CEO.
Patient recruitment is underway for a genomics-based pilot program to study opioid abuse and addiction – a first step in extending precision medicine into clinical practice for addiction, says CRO Genemarkers.
ClinicalRM – which ICON acquired in 2016 – has become ICON Government and Public Health Solutions (GPHS), providing full-service clinical trial execution and functional services to government, NGOs, and commercial customers.
“Clinical trials are care and research,” says Greg Simon, JD, President, Biden Cancer Initiative – as clinical research and healthcare professionals aim to find a collaborative solution to strengthen the connection between clinical research and healthcare.
KBI will provide services to ReForm to further develop and validate its biologic formulation platform and in turn, will gain access to ReForm’s proprietary excipient technologies.
Regulations are changing across the globe as patients, the scientific community, and other stakeholders call for increased clinical trial data transparency.
With less than a year until the full implications of Brexit set in, Parexel consultants urge the industry to not wait – assess potential risks, such as to the clinical supply chain, and take actions to mitigate them.
Project Data Sphere aims to accelerate research by providing cancer clinical trial data from various sources to “any and all scientists” – and has named pharma industry veteran Bill Louv as its new president to ensure it delivers.
